Gadolin Research

Beaumont, Texas 77702

6 studies enrolling now · 20 studies all time

What they study most

ADHD, ADHD - Combined Type, Agitation, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Type Dementia, Amyloid, Atopic Dermatitis, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity

Studies at this site

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
• A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events — Recruiting now
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Recruiting now
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age — Stopped early
• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes — Starting soon
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD — Completed
• Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
• Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea — Completed
• A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) — Stopped early
• Phase 2B/3 Double-blinded Placebo-controlled — Completed